Carvedilol (Dilatrend®) blocks β 1-, β 2-and α 1-adrenoceptors, and has antioxidant and
antiproliferative effects. Carvedilol improved left ventricular ejection fraction (LVEF) in …

Carvedilol is a β-adrenergic antagonist with vasodilatory properties (α1-antagonism), which
has been extensively evaluated in the treatment of patients with heart failure. In patients with …

Background: There is now a wealth of data supporting the use of beta-blockers in heart
failure and the additional pharmacological properties of carvedilol are thought to play an …

OBJECTIVES.: This study assessed the safety and efficacy of carvedilol in patients with heart
failure caused by idiopathic or ischemic cardiomyopathy. BACKGROUND.: Carvedilol is a …

Background: Many patients remain markedly symptomatic despite optimal current therapy
for heart failure. Beta-blockers have often been viewed as contraindicated in this group …

Patients with chronic heart failure due to left ventricular systolic dysfunction of ischemic or
nonischemic etiology have shown improvement in morbidity and mortality with carvedilol …

In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of
the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for …

Background We conducted a multicenter, placebo-controlled trial designed to establish the
efficacy and safety of carvedilol, a “third-generation” β-blocking agent with vasodilator …

Background Both metoprolol and carvedilol improve cardiac function and prolong survival in
patients with heart failure. Carvedilol has broader antiadrenergic effects than metoprolol, but …

Background Clinical trials have shown that β-adrenergic blocking drugs are effective and
well tolerated in patients with mild to moderate heart failure, but the utility and safety of these …